Patent intelligence · WO
WO 2025062334
DÉRIVÉS DE 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZÈNESULFONAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS COMME INHIBITEURS DE CDK POUR LE TRAITEMENT DU CANCER
DÉRIVÉS DE 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZÈNESULFONAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS COMME INHIBITEU…
Patent details — WO 2025062334
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Mar 27, 2025
- Expiration
- Mar 22, 2045
- Applicant
- BEIGENE SWITZERLAND GMBH [CH]
- CPC classes
- A61K 31/ 422 A I, A61K 31/ 425 A I, A61K 31/ 501 A I, A61K 31/ 506 A I
Quick answer
WO 2025062334 (DÉRIVÉS DE 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZÈNESULFONAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS COMME INHIBITEURS DE CDK POUR LE TRAITEMENT DU CANCER) is held by BEIGENE SWITZERLAND GMBH [CH]. Status: granted. Granted Mar 27, 2025. Expires Mar 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BEIGENE SWITZERLAND GMBH [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 422 A I, A61K 31/ 425 A I, A61K 31/ 501 A I, A61K 31/ 506 A I, A61K 31/ 4155 A I, A61K 31/ 4439 A I
More from BEIGENE SWITZERLAND GMBH [CH]
Related pharmaceutical patents in our USPTO index.
-
WO 2025252204
DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF
granted -
AU 2025242171
A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders
granted -
WO 2025232885
PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON
granted -
WO 2025218772
FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS
granted -
WO 2025214466
CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS
granted -
WO 2025201453
COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS
granted -
US 2025304535
KAT6 Inhibitors
granted -
US 2025290040
GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE
granted
Frequently asked questions
What is US patent 2025062334?
WO 2025062334 (DÉRIVÉS DE 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZÈNESULFONAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS COMME INHIBITEURS DE CDK POUR LE TRAITEMENT DU CANCER) is held by BEIGENE SWITZERLAND GMBH [CH]. Status: granted. Granted Mar 27, 2025. Expires Mar 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025062334?
BEIGENE SWITZERLAND GMBH [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2025062334 expire?
Our index shows an expiration date of Mar 22, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.